Drug Profile
Research programme: antisense RNA inhibitors - OPKO Health
Alternative Names: AntagoNAT; AntagoNAT Therapeutics; OPKO-CURNALatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator OPKO Health
- Class Oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dravet syndrome; Mucopolysaccharidosis I; Rett syndrome
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Dravet-syndrome in USA (Parenteral)
- 28 Oct 2021 Antisense RNA inhibitors are still in preclinical development in Dravet-syndrome in USA (Parenteral)
- 28 Oct 2021 OPKO Health and CAMP4 Therapeutics signs licensing agreement for Oligonucleotide-based AntagoNATs